Barclays plc BARC has so much small print at the beginning of its quarterly report that many readers will need a magnifying glass to avoid damage to their eye sight. The report for the 3 months to 31st March is full of gloss about how well Core is doing compared to Non Core but however they try Barclays can not gloss over the fact that in 2015 the 1st quarter dividend was 1p. This year the column is blank, and the omission gets no further mention. Does that mean what I think it means.
Group profit before tax at £793m was down 25% compared to last year, underlying profit before tax was down 2%, net attributable profit was down 7% and basic earnings per share fell from 2.9p to 2.7p, so no matter what you call it, however you wrap it up, most things were generally down which is not as good as being up. Quickly move on to the next to save my eyesight
Lifeline Scientific LCIC both revenue and profit were ahead of market expectations for the year to the end of December, with rises of 14% and 139% respectively. Growth was seen in all major markets, the company has a robust cash position and is looking forward to a strong 2016.
London Stock Exchange LSE saw income to 26th April up by 9% and claims a strong first quarter performance in all its main business divisions with LCG’s OTC, FTSE Russell and Capital Markets (that’s what they say) particularly strong, as if anybody is really interested. Then it’s full of itself over the fabulous merger with Deutsche Bourse. Let us hope and pray that the emissions of hot air are cleaner than VW”s et al.
Croda International CRDA is on the few compananies with the honesty to admit that it has benefitted from favourable currency movements, which have added 3.9% to reported sales. sales of New & Protected Products grew by 8%, well ahead of overall sales whilst margins in Personal care did well. Core sector sales overall rose by 9.8% but those old Victorian Industrial Chemicals fell by 7.8%